| Heading: |
Futibatinib |
| Question ID: |
1747332 |
| UIN: |
18238 |
| House: |
Commons |
| Date tabled: |
2024-12-05 |
| Asking Member ID: |
5031 |
| Asking Member display name: |
Mark Ferguson
|
| Asking Member handle: |
markfergusonmp
|
| Asking Member Twitter reference: |
@markfergusonmp
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the NHS supply of Futibatinib. |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2024-12-11 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
NHS England funds the use of licensed medicines that have been recommended by the National Institute for Health and Care Excellence (NICE). Futibatinib is licensed by the Medicines and Healthcare products Regulatory Agency and has been recommended by the ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |